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Abstract
The mannose 6-phosphate/IGF 2 receptor (IGF2R) is comprised of 15 extra-cellular domains that bind IGF2 and
mannose6-phosphateligands.IGF2RtransportsligandsfromtheGolgitothe pre-lysosomalcompartmentand thereafter
to and from the cell surface. IGF2R regulates growth, placental development, tumour suppression and signalling. The
ligand IGF2 is implicated in the growth phenotype, where IGF2R normally limits bioavailability, such that loss and gain of
IGF2R results in increased and reduced growth respectively. The IGF2R exon 34 (5002AOG) polymorphism (rs629849)
of the IGF2 speciﬁc binding domain has been correlated with impaired childhood growth (A/A homozygotes). We
evaluated the function of the Gly1619Arg non-synonymous amino acid modiﬁcation of domain 11. NMR and X-ray
crystallography structures located 1619 remote from the ligand binding region of domain 11. Arg1619 was located close
to the ﬁbronectin type II (FnII) domain of domain 13, previously implicated as a modiﬁer of IGF2 ligand binding through
indirect interaction with the AB loop of the binding cleft. However, comparison of binding kinetics of IGF2R, Gly1619 and
Arg1619 to either IGF2 or mannose 6-phosphate revealed no differences in ‘on’ and ‘off’ rates. Quantitative PCR,
35S
pulse chase and ﬂow cytometry failed to demonstrate altered gene expression, protein half-life and cell membrane
distribution, suggesting the polymorphism had no direct effect on receptor function. Intronic polymorphisms were
identiﬁed which may be in linkage disequilibrium with rs629849 in certain populations. Other potential IGF2R
polymorphisms may account for the correlation with childhood growth, warranting further functional evaluation.
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Introduction
The human mannose 6-phosphate/IGF2 receptor
(IGF2R) is a large (270 kDa) multi-functional type I
membrane protein and P-type lectin. The 15 extra-
cellular domains of IGF2R bind ligands that are
shuttled from the Golgi to the pre-lysosomal compart-
ment and thereafter to and from the cell surface
(Ghosh et al. 2003). Functional studies in mouse models
have shown that IGF2R ligands are involved in
embryonic growth, placental development, tumour
suppression and signalling.
Mannose 6-phosphate bound to domains 3, 5 and 9
regulates the transport of phosphomannosyl glyco-
proteins such as lysosomal proteases, and latent
transforming growth factor b1 (latent-TGFb1), where
activation of the latter to active TGFb1 occurs by
proteolytic cleavage (Dennis and Rifkin 1991, Hancock
et al. 2002a, b, Ghosh et al. 2003). IGF 2 (IGF2) binds to
domain 11 of mammalian IGF2R with high afﬁnity and
speciﬁcity (w10
K10 M), with a ﬁbronectin type II
region of domain 13 thought to act as an indirect
enhancer of afﬁnity through reduction in ‘off rate’
(Linnell et al. 2001, Williams et al. 2007, Brown et al.
2008). IGF2 is a small hydrophobic ligand (7.5 kDa)
that is normally bound to binding proteins (IGFBP’s)
that regulate bioavailability through proteolytic clea-
vage. For example, the potent embryonic growth
promoting effect of IGF2 depends on the expression
of a developmentally expressed protease, PAPPA2, that
cleaves binding proteins to release free IGF2 for signal
activation (Conover et al. 2004). The binding stochio-
metry of IGF2 to membrane bound IGF2R is 1:1, and
utilises the same binding site on IGF2 that is recognised
by binding proteins (Brown et al.2 0 0 8 ). IGF2R
sequesters free IGF2 ligand and internalises it for
intracellular degradation, and so limits activation of the
signalling receptors IGF1R and isoform A of the insulin
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of function of IGF2R results in disproportionate
embryonic overgrowth and perinatal lethality that was
rescued by the combination with knockout of Igf2
(Wang et al. 1994, Ludwig et al. 1996). Moreover, loss of
function of IGF2R has been observed in human
tumours through loss of heterozygosity and functional
missense mutations, with genetic models that also
conﬁrm the Igf2 dependency of tumours (Christofori
et al. 1994, De Souza et al. 1995, Hankins et al. 1996,
Devi et al. 1999, Kong et al. 2000, Harper et al. 2006).
These results suggest that the growth antagonist effects
of IGF2R are principally determined by the reduction
in free IGF2 ligand supply.
The relative abundance of IGF2 and IGF2R are also
regulated at the level of gene expression through
genomic imprinting. In all mammals, IGF2 is a
maternally silenced (imprinted) gene, with paternal
allele expression, whereas IGF2R is normally paternally
silenced, with maternal allele expression. Unlike other
mammals, IGF2R imprinting in humans is a poly-
morphic trait, with most individuals having bi-allelic
expression that in the mouse results in growth
retardation (Kalscheuer et al. 1993, Xu et al. 1993,
Wutz et al. 2001). Germ line loss of imprinting of IGF2
has been reported to occur in up to 10% of humans and
may be associated with an increased risk of colorectal
cancer (Cui et al. 2003, Ito et al. 2008). Observational
data have also correlated blood concentrations of IGF2
and soluble IGF2R with human birth weight and adult
height, suggesting that relative supply of ligand and
receptor may result in signiﬁcant growth effects (Ong
et al. 2000, Garrone et al. 2002).
Aside from imprinting, functional dosage of IGF2R
may also be modiﬁed by polymorphisms that either
alters gene expression or protein function. For
example, epigenetic mediated reduction in IGF2R
expression in cloned sheep accounted for the ‘large
offspring syndrome’ phenotype (Young et al. 2001).
Single nucleotide polymorphisms have been identiﬁed
throughout the 140 Kb locus and the 48 exons and
introns of human IGF2R (Killian et al. 2001). Non-
synonymous polymorphisms in coding exons have been
mapped to speciﬁc domains of the protein. For
example, the exon 34 (5002AOG) Gly1619Arg poly-
morphism generates a non-synonymous modiﬁcation
of domain 11 of IGF2R, and exists in Hardy Weinberg
equilibrium in humans (allele frequencies AZ0.15,
GZ0.85; Killian et al. 2001). Analysis of the Avon
Longitudinal Study of Parents and Children prospec-
tive cohort of normal mothers and children suggested
that babies born with the rarer AA homozygote alleles
exhibited slower growth rate kinetics during the ﬁrst
three years of post-natal development, even though
circulating IGF2 levels were similar to GG homozygotes
and heterozygote controls (Petry et al. 2005).
A comprehensive analysis of SNPs associated with the
later development of cancer has been recently reported
with IGF2R haplotypes identiﬁed that conferred an
increased risk of developing osteosarcoma (Savage et al.
2007). In this example, an intron 16 SNP was associated
with loss of methylation of a CpG island site that
presumably controlled gene expression. The impli-
cations of these, and similarSNP association studies, are
limited by the lack of functional analysis of associated
SNPs, in particular non-synonymous SNPs in ligand
binding domains of IGF2R. Here, we report the ﬁrst
comprehensive functional analysis of a non-synon-
ymous IGF2R polymorphism, Gly1619Arg of domain
11, the domain that speciﬁcally binds IGF2. We
demonstrate that this polymorphism alone has no
detectable effects on domain 11 structure, real-time
ligand binding kinetics, protein half-life and cell
surface distribution. We discuss the implications of
these ﬁndings with respect to IGF2R function and
linkage to other SNPs.
Material and Methods
Plasmids, cloning and reagents
For rat CD4 domains 3 and 4 -IGF2R chimeric
constructs (CD4-IGF2R), previously described pEFBOS
plasmids containing IGF2R domains 11, 10–13 and
1–15 were utilised (Linnell et al. 2001, Zaccheo et al.
2006). For membrane-bound IGF2R, full IGF2R insert
was derived from ATCC (J03528) using primers
(FullIGF2RNheIF2) 50-atatgctagcGCGATGGGGGCC-
GCCGCC-30 and (FullIGF2RXhoIR2) 50-gcgcctcgagT-
CAGATGTGTAAGAGGTCCTCGTCG-30, incorporating
NheI and XhoI restriction sites respectively. The
product was ligated into the pcDNA 3.1(C) vector to
generate pcDNA-IGF2R. pEGFP-N1 plasmid was from
Clontech (Saint-Germain-en-Laye, France). Protein
biotinylation was performed using the BirA biotin-
protein ligase from Avidity (CO, USA). Recombinant
human IGF2 was from Novozymes GroPep Ltd.,
(Adelaide, Australia) and latent-TGFb1 was from R&D
systems (Abingdon, UK). L-[
35S] methionine and
L-[
35S] cysteine Redivue Pro-Mix (Radioactive concen-
tration 370 MBq/ml (10 mCi/ml) with respect to
L-[
35S] methionine at the activity reference date were
obtained from Amersham. Methionine/Cysteine-free
DMEM and Protein G-Sepharose beads were from
Sigma. Mouse anti rat-CD4 antibody (MCA1022R)
and mouse anti human-IGF2R (MCA2048) were from
AbD Serotec (Oxford, UK), goat anti-mouse PE/Cy5
(M32006) was from Caltag Laboratories (Invitrogen)
and rabbit anti-E-cadherin was from Santa Cruz
Biotechnology Inc., (Heidelberg, Germany). Quick-
Change II Site-directed Mutagenesis kit was from
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Mutagenesis kit was from Finnzymes (Espoo, Finland).
ImProm-II reverse transcription system was from
Promega. Surface plasmon resonance (SPR) buffers,
chips and consumables were from GE Healthcare
(BIAcore, Chalfont, UK). The FACSCalibur system
used for ﬂow cytometry was from Becton Dickinson
(Oxford, UK).
Site-directed mutagenesis
In the pEFBOS plasmids, Gly1619Arg mutant con-
structs were generated using the Quick-Change II kit
according to the manufacturer’s protocols, using
primers (G1619R F) 50-CGTGTGCAGGCCTGAGGC-
CAGGCCAACCAATAGGCC-30 and (G1619R R)
50-GGCCTATTGGTTGGCCTGGCCTCAGGCCTGCAC-
ACG-30. For IGF2R domains 11, 10–13 and 1–15 these
are termed CD4-11, CD4-10–13 and CD4-1–15. In the
pcDNA-IGF2R plasmid, Gly1619Arg mutant constructs
were generated using the Phusion kit according to
the manufacturer’s protocols, using primers
(G1619R-phus-F) 50-GCCAGGCCAACCAATAGGCC-
CATGCTCATCT-30 and (G1619R-phus-R) 50-CTC-
AGGCCTGCACACGAAACTGATCACACTC-30.T h e
mutations were conﬁrmed by DNA bi-directional
sequencing performed by the sequencing service
(School of Life Sciences, University of Dundee, Scot-
land) using Applied Biosystems Big-Dye Version 3.1
chemistry on an Applied Biosystems model 3730
automated capillary DNA sequencer.
IGF2R domain 11 G1619R
To construct IGF2R domain 11 Gly1619Arg expression
vector, domain 11 Gly1619Arg was ampliﬁed by PCR
from pEFBOS-IGF2R-domain11 Gly1619Arg and
cloned into the NdeIa n dXhoI restriction sites of
pET26b (Novagen) using standard methods. The
authenticity of the clones was veriﬁed by sequencing.
Wild-type domain 11 had been previously cloned into
pET22b for Escherichia coli expression (Brown et al.
2002).
15N-labelled wild-type and Gly1619Arg domain
11 were expressed in E. coli BL21(DE3) grown in M9
media supplemented with 1 g/l of
15NH4Cl as the sole
nitrogen source and refolded using established proto-
cols (Williams et al. 2007). Owing to slightly different
cloning strategies, wild-type domain 11 had a
C-terminal hexahistidine tag while the Gly1619Arg
domain 11 construct lacked any additional amino acids.
NMR spectroscopy
NMR samples typically contained w 250 mM protein
dissolved in 600 ml of 20 mM sodium acetate (pH5.5),
1 mM EDTA, 1 mM benzamidine and 100 mM NaN3 in
95% H2O/5% D2O. Two dimensional
1H-
15N hetero-
nuclear single quantum coherence spectra were
recorded at 25 8C on a Varian 600 MHz INOVA
spectrometer equipped with a triple resonance probe.
Spectra were acquired with 1024
1H complex points in
the t2 dimension and 128 points in the
15N dimension,
and spectral widths of 7000 Hz in
1H and 2000 Hz in
15N. Data were processed using NMRPipe (Delaglio
et al. 1995) and analysed with CCPN Analysis version
1.015 (Vranken et al. 2005).
Expression of CD4-IGF2R chimeras and membrane
bound IGF2R
The CD4-IGF2R chimeric constructs were transiently
expressed in 293T cells using Fugene 6.0 (Roche).
Brieﬂy, 4 mg DNA and in a 6:1 plasmid:Fugene ratio
were added to cells and grown for 5 days in serum free
media (DMEM; Sigma-D5796) with 4500 mg/l glucose,
L-glutamine (584 mg/l), NaHCO3 (3.7 g/l) and pyro-
doxyl HCl (4 mg/l) with added 50 u/ml penicillin,
50 mg/ml streptomycin. Spent culture supernatants
were collected, and cells were cleared by centrifugation.
Cell lysis and recombinant CD4-IGF2R chimeras’
detection was with a CD4 sandwich ELISA as described
(Davis et al. 1990). Protein biotinylation, SDS PAGE and
western blotting were also performed as previously
described (Linnell et al. 2001, Zaccheo et al. 2006). The
full length IGF2R constructs were transiently co-ex-
pressed in 293Tcells with eGFP plasmid using lipofecta-
mine (10 ml) (Invitrogen) using 3.6 mg pcDNA-IGF2R
and 0.4 mg eGFP-N1 plasmid in antibiotic-free growth
media (DMEM with 2mM glutamine and 10% fetal
bovine serum). The medium was changed 24 h post-
transfection to serum-free medium, and cells were
prepared for ﬂow cytometry 48 h post-transfection.
Surface plasmon resonance kinetic analysis
Kinetic analysis by SPR was conducted as previously
described (Zaccheo et al. 2006) using a BIAcore 3000
biosensor (BIAcore). All SPR experiments were per-
formed at 25 8C in HBS-EP (10 mM Hepes (pH 7.4),
150 mM NaCl, 3 mM EDTA and 0.005% (v/v)
surfactant P20) at a ﬂow-rate of 40 ml/min. After
pre-conditioning, the sensor chip with three 1 min
injections of 1 M NaCl, 50 mM NaOH, either w 600 RU
of recombinant biotinylated CD4-11, w 1600 RU of
recombinant biotinylated CD4-10–13 or w 3300 RU of
recombinant biotinylated CD4-1–15 were immobilised
on a Sensor Chip SA by afﬁnity capture to streptavidin.
Kinetic experiments consisted of a 2–5 min injection of
analyte followed by a 150–200 s dissociation phase in
HBS-EP running buffer, after which the binding surface
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www.endocrinology-journals.org Journal of Molecular Endocrinology (2009) 42, 341–356was regenerated with a 2 min injection of 2 M MgCl2.
Kinetic parameters were determined by global ﬁtting of
sensorgrams to a two-state (conformational change)
binding model using BIA evaluation software version
4.0.1. In all cases, the minor component made an
insigniﬁcant contribution to the overall afﬁnity and, as
such, only the kinetic parameters of the major binding
component were used. For each interaction, the
dissociation afﬁnity constant (KD) were also calculated
by ﬁtting of the response of each concentration at
equilibrium to a steady-state afﬁnity model using
BIAevaluation.
Using the SA sensor chip with immobilised WT CD4-
1–15 and G1619R CD4-1–15, competition assay experi-
ments were run at a ﬂow-rate of 40 ml/min and
consisted of a co-inject of a ﬁrst 100 ml injection of
either (130 nM) recombinant human IGF2 or (30 nM)
latent TGFb1, followed by a second 100 ml injection of a
1:1 mixture of both analytes at the same above
concentrations or 1:1 mixture of one analyte with
buffer. A control experiment was run on the same
sensor chip, where a co-inject of a ﬁrst 100 ml injection
of buffer (HBS-EP), followed by a second 100 ml
injection of a 1:1 mixture of each analyte at the same
above concentrations with buffer.
Analysis of the competition experiments were
performed by quantifying the amounts of bound
analyte from the second injection of each co-inject.
This was assessed from the response amplitude (RU)
and compared with control injections. For both kinetic
and competition analyses, a blank ﬂow-cell was used for
in-line reference subtraction of changes due to
differences in refractive index of running buffer versus
sample and a buffer-only injection was used to subtract
instrument noise and drift. Injections were performed
in duplicate for each concentration and in a random-
ised order.
Quantitative RT PCR
RNA was extracted from 293T cells 5 days post-
transfection, using Trizol (Invitrogen) in accordance
with the manufacturer’s protocol. The extracted RNA
was then treated with DNase (Ampliﬁcation grade,
Invitrogen) and reverse transcribed. Subsequently, real-
time PCR was performed using the SYBR Green
QuantiTect RT-PCR Kit (Qiagen) and the Mx3000P
real-time cycler in accordance with the manufacturer’s
instructions. Data were analysed in accordance with
manufacturers’ instructions.
[
35S]-methionine and [
35S]-cysteine pulse-chase
In 9.5c m
2 6-well plates, 293T cells were transfected by
Fugene 6 using 1 mg plasmid DNA and a 6:1
plasmid:Fugene ratio in growth media (DMEM with
2 mM glutamine, antibiotics and 10% fetal bovine
serum). Transfected cells were incubated at 37 8Ci na
humidiﬁed incubator supplied with 5% CO2 for 24 h
Figure 1 Structural localisation of Gly1619 of IGF2R domain 11. (A) Crystal structureof IGF2R domain 11–13
bound to IGF2(2) (PDB: 2V5P). Gly1619 is located in a long loop between b-strands G and H. Modelling of
the arginine replacement of glycine (Gly1619Arg) suggests that the Gly1619Arg polymorphism may interact
with a group of charged residues of the ﬁbronectin type II (FnII) domain of domain 13, rendered as pink sticks,
e.g. Glu1916 and Glu1915. (B) Comparison of the
1H-
15N HSQC spectra of wild-type (Gly1619, black) and
Arg1619 (red) domain 11 recorded at 600 MHz at pH5.5, 25 8C. Side chain NH2 groups of Asn and Gln are
indicated by lines parallel to the
1H axis and the Gly1619Arg polymorphism is boxed. Changes in the spectra
due to differences in the constructs are highlighted with an asterisk.
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twice with PBS and incubated for 30–60 min in 1 ml
starvation medium (methionine/cysteine-free DMEM,
50 u/ml penicillin, 50 mg/ml streptomycin and 2 mM
glutamine). For metabolic labelling, the starvation
medium was replaced with 500 ml/well of pulse medium
(starvation medium C0.1 mCi/ml [
35S]-methionine
and [
35S]-cysteine Redivue Pro-Mix) and pulsed for
1 h or 12 h at 37 8C and 5% CO2. Metabolic labelling
was stopped by adding 500 ml per well of chase medium
(starvation medium supplemented with cold 5 mM
cysteine and 5 mM methionine), washed and incubated
1 ml per well of chase medium. After the selected
chase time, supernatants were recovered, centrifuged at
5000g for 5 min, immediately snap-frozen in liquid
nitrogen and stored at K80 8C until all chase samples
were collected. For each selected chase time, cells were
incubated for 30 min on ice (4 8C) in 500 ml/well lysis
Figure 2 Protein expression and real-time kinetic analysis of wild-type and Gly1619Arg IGF2R binding to
IGF2. (A) Western blot detection of the expressed and biotinylated recombinant proteins. Soluble CD4
chimeric proteins were biotinylated, subjected to SDS-PAGE and directly probed with streptavidin
conjugated to alkaline phosphatase. (B) Representative sensorgrams depicting injections of recombinant
IGF2 at 2, 4, 8, 16, 33 and 134 nM binding to immobilised CD4-11 chimeric proteins; WT domain 11 (WT
11) and Gly1619Arg (abbreviated to G1619R) domain 11 (G1619R 11). (C) and (D) Representative
sensorgrams depicting duplicate injections of recombinant IGF2 at 0.2, 0.5, 1, 2, 4, 8, 16, 32, 64, 128 nM
binding to CD4-11 chimeric proteins; wild-type recombinant 10–13 domains (WT 10–13), Gly1619Arg
recombinant 10–13 domains (Gly1619Arg 10–13), wild-type recombinant 1–15 domains (WT 1–15) and
Gly1619Arg recombinant 1–15 domains (G1619R 1–15). Constructs and ranges of analyte concentrations
are indicated. Grey lines represent the global ﬁtting of the data set to a two-state (conformational change)
binding model (see also Table 1).
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MgCl2, 1:1000 protease inhibitor cocktail (Sigma
P3840), 1:1000 PMSF from a 200 mM Stock in
Isopropanol). Cell lysates were then snap frozen in
liquid nitrogen and stored at K80 8C. For immuno-
precipitation (IP), liquid scintillation counting and
protein assays, unfrozen samples were centrifuged at
10 600g for 10 min to pellet the nuclei and remove
debris. Immuno-precipitation was performed using
20 ml Protein G-Sepharose (2 mg/ml) beads for each
sample, where PBS-washed beads and 1 ml antibody
were incubated with slow rotation overnight at 4 8C
with either 250 ml of the recovered supernatants or
50 ml cell lysates in a total volume 600 ml. Pellets were
then washed three times with PBS and prepared for
SDS-PAGE analysis by ﬁnal re-suspension in
15 ml/pellet of 5!Sample buffer (200 mM Tris–HCl
pH 6.8, 10% SDS, 50% glycerol, 5% 2-mercaptoethanol,
0.05% bromophenol blue) and 5 min boiling at 95 8C.
Immuno-precipitation products were loaded in 5%
(w/v) polyacrylamide gels and were run at 200 V for
35 min, dried on 0.5 mm Whatman ﬁlter paper in a
vacuum-heated gel dryer and exposed to a BioRad
phosphor imaging screen.
Scanning densitometry was used to quantify radio-
activity, and values were expressed relative to a loading
controloftotalradioactivityineachsample.Thelatterwas
determined by total liquid scintillation counting using
PerkinElmer scintillation cocktail (Ultima Gold LLT).
Flow cytometry
Cells were detached from plates using 0.1 mM EDTA.
For cell surface detection with an intact cell membrane,
cells were not ﬁxed or permeablised, however, for total
expression, cells were ﬁxed in 1ml paraformaldehyde
(2% w/v in PBS, pH 7.4) at 4 8C for 30 min and
permeablised in 0.1% v/v Triton in 2% w/v parafor-
maldehyde at 4 8C for 30 min.
Cells were treated with 1 ml buffer (1% BSA in PBS)
and stained using 100 ml buffer with 1:50 diluted
primary antibody (AbD Serotec mouse anti-human
IGF2R CD222) and incubated at room temperature
for 1 h at 4 8C. Cells were than washed and incubated in
100 ml buffer with 1:50 diluted secondary antibody
(Caltag goat anti-mouse PE/Cy5) for 1 h at 4 8C. Cells
were analysed using a Becton Dickinson FACSCalibur
system and data were analysed using WinMDI 2.8
software.
Single nucleotide polymorphism bioinformatics
analyses
The allele frequency of rs629849 and linkage disequil-
brium of IGF2R around this SNP was investigated using
publicly available genotype data from the HapMap
(Han Chinese, Japanese, and Yoruba) (Frazer et al.
2007), SNP500Cancer (African/African American,
Caucasian, Hispanic, and Paciﬁc Rim) (Packer et al.
2006) and the Multi-Ethnic Cohort (Black, Hawaiian,
Japanese, Latino, and White) (Kolonel et al. 2004).
Haploview (version 4.1) was used to calculate measures
of linkage disequilibrium (LD). These measures
included absolute D0 (a measure of the covariance of
allele counts for two SNPs under the assumption of
Hardy–Weinberg equilibrium), the 95% conﬁdence
intervals for D0, LOD scores (log of the likelihood ratio,
a measure of the conﬁdence in the value of D0), and the
Table 1 BIAcore kinetic analysis of IGF2 and latent TGFb1 binding to recombinant IGF2R chimeric domains
Immobilised ligand
on SA sensor chip
ka1 (1/Ms)
(!10
5)
kd1 (1/s)
(!10
K2)
ka2 (1/Ms)
(!10
K3)
kd2 (1/s)
(!10
K3)
KD (M)
(!10
K9)
Relative
KD X
2
Steady state
KD (M)
(!10
K9)
Analyte
IGF2 CD4 IGF2R-Dom11
WT 8.65 2.68 2.01 1.37 31.21 2 .13 6 .5
Gly
1619Arg 7.03 2.44 1.27 2.05 34.71 .11 3.23 6 .3
CD4 IGF2R-Dom10-13
WT 1.23G0.14 1.72G0.53 .51G2.19 2.15G0.82 1.35G0.27 1 11.12 .76G0.31
Gly
1619Arg 1.21G0.12 1.68G0.43 3.85G2.82 4.14G1.36 1.37G0.26 1.01 11.22 .83G0.31
CD4 IGF2R-Dom1-15
WT 1.75G0.19 2.15G0.13 2.29G0.22 4.68G1.79 1.27G0.21 1 .61 .99G0.3
Gly
1619Arg 1.67G0.16 2.09G0.11 2.54G0.23 1.86G0.61 .29G0.21 .01 0.92 .09G0.3
Latent
TGFb1
CD4 IGF2R-Dom1-15
WT 3.33 0.61 1.93 0.0016 18.31 2 .4/
Gly
1619Arg 2.99 0.58 1.90 .0033 19.41 .06 2.5/
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2) statistic (correlation coefﬁcient for the
pairwise comparison of the SNPs) (Barrett et al. 2005).
Results
Structural location, conformation and modelling of
Gly1619Arg
We ﬁrst determined the localisation of Gly1619 in
relation to the IGF2 binding site of human IGF2R
domain 11. We utilised our high resolution NMR and
X-ray crystallographic structures of human IGF2 bound
to 11–13 of IGF2R at 4.1A ˚ (Williams et al. 2007, Brown
et al. 2008). Both the solution structure of domain 11 of
IGF2R, and the modelled IGF2 binding interaction
using HADDOCK, located Gly1619 in the GH loop
region, distant from the cluster of differentiation, AB
and FG that formed the IGF2 binding site (Fig. 1A)
(Williams et al. 2007, Brown et al. 2008). IGF2 induced
conformational changes in domain 11 structure
detected by NMR were predominantly located in the
binding loops (AB, cluster of differentiation and FG
loops) rather than the carbon backbone of the b-barrel
structure.
Detailed examination of domain 11
1H-
15N hetero-
nuclear single quantum coherence (HSQC) spectra
showed that Arg1619 modiﬁcation did not signiﬁcantly
alter protein conformation when compared with
Gly1619 (Fig. 1B). Moreover, comparison of the crystal
structures of ligand free domains of 11–14 at 2.9A ˚, and
domains 11–13 with IGF2 bound at 4.1A ˚, also showed
no conformational change in either the localisation or
juxtaposition of G1619 (see Supplementary Figure S3
of Brown et al. (2008)). Modelling of the arginine
replacement of glycine revealed a number of new
potential electrostatic interactions with Glu1916 and
Glu1915 of the ﬁbronectin type II (FnII) domain of
domain 13 (Fig. 1A). These new interactions may help
to stabilise the ﬁbronectin type II domain, and alter the
orientation of the interaction with the AB loop of
domain 11 that can modify IGF2 binding (Brown et al.
2008). The FnII residues interacting with the AB loop
are on the same long loop as those that could possibly
interact with Gly/Arg1619, namely Ser1921 and
Arg1922, and possibly Trp1639. As a result of the
location of Gly1619 between domain 11 and 12, it is also
possible that Arg1619 may alter the conformation
between domains on ligand binding of IGF2, which
may not only alter IGF2 interactions with domain 11,
but may also alter the subsequent binding of mannose
6-phosphate to domain 3, 5 and 9.
Real-time analysis of IGF2 ligand binding using SPR
Analysis of the domain 11 structure suggested that the
Gly1619Arg polymorphism may alter the IGF2 binding
interaction indirectly by modifying the interaction
between the AB loop of IGF2R domain 11 and the
FnII domain of domain 13. We had previously mutated
the AB loop residues and identiﬁed Glu1544 as an
important residue in the interaction with IGF2, and
when mutated to a Lys a sixfold enhanced afﬁnity to
IGF2 was observed (Zaccheo et al. 2006). Moreover,
when we deleted the FnII domain in domain 13, we
detected an increased ‘off rate’ of the interaction by
tenfold with IGF2, which could be partially rescued
by the Glu1544Lys mutation (Brown et al. 2008). By
utilising protein expression systems we have previously
Figure 3 Real-time kinetic evaluation of the binding of latent-
TGFb1 to wild-type and G1619R IGF2R domains 1–15.
Representative sensorgrams depicting duplicate injections of
recombinant latent TGFb1a t0 .18, 0.37, 0.75, 1.5, 3, 6, 12 and
24 nM binding to immobilised CD4-11 chimeric proteins; wild-type
recombinant 1–15 domains (WT 1–15) (A) and Gly1619Arg
recombinant 1–15 domains (G1619R 1–15) (B). Constructs and
ranges of analyte concentrations are indicated. Grey lines
represent the global ﬁtting of the data using a two-state
(conformational change) binding model (see also Table 1).
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directed mutagenesis, and expressed both soluble His-
tagged IGF2R domain 11 using Pichia pastoris, and
chimeric soluble rat CD4 tagged IGF2R domains 11,
10–13 and 1–15 using 293T cells (Linnell et al. 2001,
Zaccheo et al. 2006). Proteins were expressed and
single bands identiﬁed on western blots (Fig. 2A).
Proteins were biotinylated and immoblised on BIAcore
biosensor chips and recombinant IGF2 ligand was
passed over the sensor surface at increasing concen-
trationandathighﬂow-rates(40 ml/min).Theresulting
sensograms were ﬁtted using a two-state conformational
Figure 4 Real-time kinetic evaluation of IGF2 and latent-TGFb1 competition binding to CD4-chimeric wild-type and G1619R IGF2R
domains1–15.(A)Representativesensorgramsofcontrol100 mlinjectionsofHBS-EPbufferfollowedby100 mlofHBS-EPbuffercontaining
asingleanalyte,withsubsequentbindingtoimmobilisedrecombinantCD4-chimericGly16191–15domains(WT,1–15)andArg16191–15
domains(G1619R1–15).130nM IGF2inbuffer(black lines), 30 nM latent-TGFb1 inbuffer(redlines)areshowntogether.(B)Theeffectof
IGF2 pre-binding on the subsequent latent-TGFb1 binding to WT 1–15 and Gly1619Arg 1–15. Representative sensorgrams are shown.
InitialinjectionsofIGF2(130 nM)alonewerefollowedeitherbyinjectionofthesameconcentrationofIGF2(130 nM)inbuffer(blacklines)or
130 nMIGF2with30 nMlatent-TGFb1(redlines).Similarlatent-TGFb1bindingproﬁleswereobserved.(C)Theeffectoflatent-TGFb1pre-
binding on the subsequent IGF2 binding to WT 1–15 and Gly1619 Arg 1–15. Injections of latent-TGFb1 (30 nM) were either followed by
injectionof30 nMlatent-TGFb1inbuffer(redlines),30 nMlatent-TGFb1plus130 nMIGF2(blacklines)or130 nMIGF2onlyascontrol(blue
lines). The expected binding proﬁle of IGF2 was not detected, and the extent of inhibition was similar in Gly1619 and Arg1619.
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shown in Fig. 2B–D). We had previously validated these
biosensor kinetic assays and have shown them to be
sensitive enough to detect subtle changes in binding
kinetics with single point mutations (Zaccheo et al.
2006). Comparison of domain 11 alone, domains 10–13
anddomains1–15withandwithout Gly1619Argshowed
no signiﬁcant difference in association and dissociation
kinetics(Table1).Moreover,whenbiotinylatedIGF2was
immobilised, the binding proﬁles of soluble receptor
constructs showed mass transport effects but no
differences between Gly1619 and Arg1619, suggesting
that differences were not masked by any tethering effect
of immobilised receptors (not shown). Thus, we could
notdetectanydifferenceinafﬁnitybetweenGly1619and
Arg1619usingsingleandmultipledomainrecombinant
proteins and SPR.
Real-time analysis of mannose 6-phosphate ligand
binding using SPR
We next tested the effects of the Gly1619Arg mutant
domain 1–15 proteins on binding to mannose
6-phosphate. For this reaction, we utilised mannosy-
lated latent-TGFb1 that we had previously tested
(Linnell et al. 2001, Zaccheo et al. 2006). Concentration
dependent binding sensorgrams were ﬁtted using a
global model (expected stoichiometry of 2:1, Fig. 3
representative sensorgrams) and association and
dissociation rates calculated (Table 1). Again, we could
not detect signiﬁcant differences in binding to latent-
TGFb1 alone. Previous reports suggested that binding
of IGF2 and latent-TGFb1 to IGF2R may be mutually
exclusive (Kiess et al 1989, 1990). In order to test the
hypothesis that Gly1619Arg mutation might have
altered these interactions, we designed an experiment
where either IGF2 or latent-TGFb1 was pre-bound to
immobilised biotinylated CD4-1–15 on a streptavidin
biosensor chip (Fig. 4). Kinetics of binding to single
analyte was ﬁrst compared (Fig. 4A), before IGF2 was
pre-bound at 130 nM (saturation concentration),
followed by latent-TGFb1 (30 nM) combined with
IGF2 (130 nM; Fig. 4B). Examination of sensorgrams
revealed similar binding of latent-TGFb1 irrespective of
whether IGF2 was pre-bound (Fig. 4B). However, when
latent-TGFb1 was loaded on the sensor chip prior to
IGF2, the subsequent binding of IGF2 was signiﬁcantly
impaired when co-injected with latent-TGFb1 or alone
as a control, indicating that occupied mannose
6-phosphate binding sites impaired IGF2 binding.
There were no signiﬁcant differences in binding
kinetics detected between Gly1619 (wild-type) and
Arg1619 (Fig. 4C). Thus, we conﬁrmed previous reports
that mannose 6-phosphate binding may compete with
the IGF2 interaction, an effect presumed to be due to
steric hindrance, although indirect conformational
changes in binding loops of domains 3 and 9 have
not been excluded (Kiess et al. 1989, 1990).
Figure 5 Quantiﬁcation of mRNA and protein levels in 293T cells transfected with wild-type (WT) and
Gly1619Arg IGF2R CD4-1–15. (A) Relative expression of CD4-IGF2R Gly1619Arg mRNA relative to wild-
type (1–15 and 10–13) using quantitative RT-PCR. Three separate single comparisons with single value WT
taken arbitrarily as 1 and G1619R taken as a ratio. Values are meanGS.E.M. of three different experiments.
Expression was normalised relative to GAPDH. The efﬁciency of the conducted PCR experiments, as
assessed fromstandard curves,was between95 and 100%. (B) Quantiﬁcation of expressed solubleproteins
using a CD4 inhibition ELISA suggested that there was no difference in CD4-1–15 proteins but potentially
reduced relative amounts of CD4-10–13 Arg1619. MeanGS.E.M. of six different experiments. P values
*0 .043, ** 0.015 using students t-test. (C) Western blot of endogenous and over-expressed wild-type and
G1619R membrane bound IGF2R 1–15 (non-CD4 chimeric) in transfected 293T cell lysates. Samples were
subjected to SDS-PAGE and probed with rabbit anti-human IGF2R. The blot was re-probed using rabbit anti-
E-cadherin loading control.
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Arg1619 in mammalian cells
In order to determine whether the polymorphism
altered either RNA or protein stability, we transiently
over-expressed both soluble and membrane bound
versionsofIGF2Rdomains1–15in293Tcells.Messenger
RNAexpressionandproteinlevelswerequantiﬁedusing
quantitative RT-PCR and a previously described CD4
inhibition ELISA (for soluble CD4-1–15 proteins)
respectively (Davis et al. 1990, Linnell et al. 2001). No
signiﬁcant changes in mRNA levels and 1–15 protein
constructs were detected (Fig. 5A and C), although a
signiﬁcant relative reduction in level of the CD4-10–13
Arg1619 and CD4-1–15 Arg1619 was observed. It was
possible that either selective proteolysis or alteration in
protein half-life accounted for these results with CD4
chimeric proteins, the former a mechanism of IGF2R
turnover (Clairmont and Czech 1991), the latter having
been described for mutations of the membrane
receptors (Nakayama et al. 2004, Sharma et al. 2004).
In order to further investigate these results, we next
performed
35S-methionine pulse-chase experiments in
293T cells transiently transfected with CD4-1–15
Gly1619 and CD4-1–15 Arg 1619 to generate soluble
proteins, and 1–15Gly1619 and 1–15Arg1619 to gen-
erate membrane bound proteins. Cell lysate and
supernatant samples were immuno-precipitated with
antibodies to either CD4 or IGF2R depending on
whether soluble or membrane bound proteins were
expressed respectively. SDS protein gels were exposed
and quantiﬁed by phosphorimaging, and radioactivity
expressed relative to a control of the total radioactivity
in the sample. Following a 1 h pulse and 96 h chase,
soluble CD4-1–15 proteins were chased into the
supernatants from cell lysates with similar kinetics and
levels between Gly1619 and Arg1619 (Fig. 6A and B).
For membrane bound proteins, a 12 h pulse resulted in
higher radio-labelled protein levels in cell lysates
compared with a 1 h pulse, with no signiﬁcant overall
differences observed between Gly1619 and Arg1619
half-life in cell lysates and cell culture supernatants
(Fig. 6C–F). We concluded that differences in protein
abundance observed following transient transfection
were not related to altered half-life of IGF2R proteins.
Surface membrane distribution of IGF2R protein
Finally, we utilised membrane bound 1–15 Gly1619 and
A r g 1 6 1 9c o - e x p r e s s e dw i t he G F Pr e p o r t e rp l a s m i d
following transient co-transfection in order to determine
whether membrane distribution of IGF2R was altered.
Immuno-ﬂuorescence of unﬁxed cells with a mouse anti-
human IGF2R antibody did not show altered distribution
with Arg1619 (not shown). Two colour ﬂow cytometry was
then utilised to quantify surface expression of IGF2R in
unﬁxed 293Tcells and total IGF2R in cells that had been
ﬁxed and permeablised (Fig. 7). Following control
transfections to set thresholds of detection (not shown),
eGFP positive and PE/Cy5 anti-IGF2R positive cells were
quantiﬁed,andagainshowednodifferencesinabundance
and membrane protein localisation between genotypes.
Genetic variation around IGF2R Gly1619Arg
The frequency of the rs624849, Exon 34–93 AOG,
Gly1619Arg SNP is variable between different human
populations. Using publicly available databases, popu-
lation-speciﬁc genetic variation and linkage disequi-
librium (LD) of Gly1619Arg was evaluated. The
frequency of the A allele ranged from 0 in the HapMap
Yoruba subjects to 0.25 in Paciﬁc Rim subjects from
SNP500Cancer (Table 2). This SNP was not in Hardy–
Weinberg equilibrium in Caucasian subjects from both
HapMap and SNP500Cancer.
LD was assessed between rs629849 and SNPs 20 kb
upstream and downstream of rs629849 with minor
allele frequencies greater than or equal to 0.01.
rs629849 was not in strong LD (R
2O0.8) with any
SNPs in these regions. SNPs with R
2 values greater than
0.3 and D0 values O0.8, suggestive, but not strongly
Figure 6 IGF2R [
35S] radiolabelled pulse-chase in transfected 293T cells. (A and B) Soluble CD4-IGF2R chimeric proteins. Pulse-chase
analysis of IGF2R wild-type and Gly1619Arg CD4-1–15 processing by 293T cells transiently transfected and pulsed for 1 h with [
35S]-
cysteineand [
35S]-methionine, and chasedin coldmedia asdescribedin methods.Supernatantsand cell lysateswerecollectedat chase
time pointsas indicated,immuno-precipitatedusing mouseanti-ratCD4 antibody,and subjected toSDS-PAGE.Controlswereeither cell
lysates or supernatants of non-transfected 293T cells. Densitometry data (B) were obtained from phosphor-imager scanned protein
bands (times as indicated) and measured using ImageQuant software and normalised against total [
35S] liquid scintillation per chase
sample (A). (B) Upper curves depict the total [
35S] liquid scintillation counts of 50 ml samples of corresponding cell lysates. (C—F)
Membrane bound non-CD4 IGF2R. Pulse-chase analysis of wild-type and Gly1619Arg membrane bound 1–15 IGF2R (non-CD4
chimeric) processing by 293T cells. Transiently transfected 293T cells that expressed wild-type or Gly1619Arg 1–15 IGF2R were pulsed
for 1 h (C and D) or 12 h (E and F) with [
35S]-cysteine and [
35S]-methionine, then chased in cold media. Cell lysates were collected at
various chase time points (as indicated) and immuno-precipitated using mouse anti-human IGF2R antibody, and then subjected to SDS-
PAGE to detect 1–15 IGF2R. Controls are cell lysates of non-transfected 293T cells and pre-pulse samples (Pre) were taken prior to
metabolic labelling. Again, example phosphor-images (C and E) were quantiﬁed using ImageQuant software and normalised against
total [
35S] liquid scintillation per chase sample. (D) and (F) The upper curves depict the total [
35S] liquid scintillation counting of 50 ml cell
lysates and the lower curves depict the relative band intensity.
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descent from HapMap and SNP500 (Table 3). These
SNPs were in nearby introns.
Discussion
Disruption of the function of IGF2R has potent
consequences for IGF2 dependent overgrowth of the
mammalian embryo (Wang et al. 1994, Ludwig et al.
1996, Wylie et al. 2003). Frequent mutation and loss of
function of IGF2R in human tumours have also
implicated the selective growth advantage of cells
lacking IGF2R (De Souza et al. 1995, Hankins et al.
1996, Byrd et al. 1999, Kong et al. 2000). Of the ligands
that bind IGF2R, IGF2 appeared to be the most potent
in terms of gross effects on growth control. As IGF2
binds IGF2R at a selective binding site in domain 11,
Figure 7 Flow cytometry of anti-IGF2R labelled 293T cells over-expressing membrane bound IGF2R
domains 1–15. 293T cells were co-transfected with membrane bound (non-CD4 chimeric) IGF2R 1–15
(pcDNA IGF2R) and eGFP (pEGFP-N1) plasmids as described in methods. Forty-eight h post-transfection,
cells were either ﬁxed with paraformaldehyde (2% w/v) or permeablised with Triton X100 (0.1% v/v) (A) or
ﬁxed with 4% (w/v) paraformaldehyde alone (B). Cells were incubated with mouse anti-human IGF2R,
detected using PE/Cy5 secondary antibody (goat anti-mouse), co-labelling data collected with a
FACSCalibur ﬂow cytometer with minimal compensation, and then analysed using WinMDI 2.8 software.
Non-transfected and secondary antibody controls were used to set background thresholds (not shown)
Geometric means of staining are expressed GS.E.M.( nZ5).
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isms of this domain remain strong candidate modiﬁers
of human embryonic and tumour growth.
A number of observational approaches have been
taken to assess the functional signiﬁcance of the 1619
position of domain 11 of IGF2R. During evolution of
IGF2R, the receptor acquired an IGF2 ligand binding
function that was associated with a number of amino
acid mutations of the domain 11 binding site, yet
Gly1619 appeared to be a highly conserved amino acid
during the evolution of birds (chicken) to mammals
(Clairmont and Czech 1989, Yandell et al. 1999, Brown
et al.2 0 0 2 , 2008). This evolutionary observation
suggested that the non-synonymous SNP at 1619
would be unlikely to be involved in a direct interaction
with IGF2. Our structural studies have also supported
this notion, as the 1619 residue was remotely located
with respect to the IGF2 binding site. In addition, IGF2
induced conformational changes in the binding site
loop residues but not the 1619 residue, and suggested
that any effect on IGF2 binding was likely to be indirect.
Modelling of Arg1619 supported potential indirect
effects on the FnII domain that subsequently may have
lead to alteration of binding site interactions through
the AB loop (Zaccheo et al. 2006). These observations
led us to directly mutate Gly1619 to Arg1619 and to
compare receptor function.
A report had correlated slower human childhood
growth rate in the rare IGF2R Arg1619 (A/A)
homozygotes, yet our data suggested that this amino
acid change alone was non-functional in terms of IGF2
and mannose 6-phosphate ligand binding, protein
half-life and cell membrane distribution (Petry et al.
2005). It is important to state that the implications of
our experiments do not alter the interpretation of the
Table 2 Genetic variation of rs629849 (Ex34–93 AOG,
Gly1619Arg) amongst populations
Population
Number of
individuals
A allele
frequency
HapMap
a Han Chinese 42 0.143
Japanese 43 0.174
Yoruba 60 0
SNP500Can-
cer
African/African
American
24 0.021
Caucasian
b 31 0.194
Hispanic 23 0.130
Paciﬁc Rim 24 0.250
Multi-ethnic
Cohort
Black 69 0.029
Hawaiian 69 0.094
Japanese 68 0.114
Latino 69 0.066
White 68 0.103
a
Data from CEPH Caucasians were not available from HapMap.
b
rs629849 was not in Hardy–Weinberg equilibrium in this group.
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of IGF2, and inverse correlation with soluble IGF2R
and human growth (Ong et al. 2000, Garrone et al.
2002). However, our data make it difﬁcult to directly
attribute the phenotypic growth effects with
Gy1619Arg to IGF2R receptor function. Even though
the observations of Petry et al. (2005) are uncon-
ﬁrmed, our observations do not alter the Arg1619
correlation observed (Kaku et al. 2007), as there are a
number of potential explanations that might reconcile
these sets of data.
Firstly, it was possible the assays we utilised may have
been insensitive to subtle changes in receptor function.
For real-time analysis of recombinant protein
interactions, we are conﬁdent that the validated
approach taken here would have been sensitive enough
to deﬁne functional variation, such as the fundamental
binding interaction between IGF2 and IGF2R. This was
unaltered between Gly1619 and Arg1619. Importantly,
we have also shown that the competitive binding
between mannose 6-phosphate and IGF2 binding was
also unaltered. As IGF2R cycles between the endoplas-
mic reticulum, Golgi and the pre-lysosomal compart-
ment, it was possible that modiﬁed function may have
occurred as a result of either altered trafﬁcking,
distribution or proteolysis (Ghosh et al. 2003). It is
well established that the trafﬁcking and distribution
functions of IGF2R depend on the cytoplasmic domain
that is remotely located with respect to 1619, which
meant that it would have been highly unlikely that
Gly1619Arg would have altered trafﬁcking. However,
several important non-synonymous polymorphisms of
membrane receptors have functional effects that were
related to altered protein half-life. For example, the
chemokine receptor CCR2-Val64Ile polymorphism
resulted in protein with prolonged half-life that had
explained the delayed progression to AIDS in HIV
infected humans with 64Ile (Nakayama et al. 2004). In
addition, deletion of Phe508 of the CFTR gene leads to
cystic ﬁbrosis because of altered folding, stability and
plasma membrane half-life (Sharma et al. 2004). Here,
we directly addressed this question and performed
quantitative pulse-chase and ﬂow cytometry experi-
ments that suggested that Gly1619Arg did not signi-
ﬁcantly alter the rate of protein production, processing,
proteolysis and membrane distribution. The only
remaining functional mechanism that we did not
directly test was the potential interaction of residue
1619 with domain 12, and the potential for indirect
modiﬁcation of IGF2R dimerisation (Kreiling et al.
2005). We have previously detected dimerisation of
1–4% of recombinant domain 11–12 and 11–13 using
analytical ultracentrifugation, corroborating our obser-
vation of structural juxtaposition of domain 12 in
crystals and the data obtained using epitope tagged
IGF2R (Kreiling et al. 2005, Brown et al. 2008). Ligand
binding does not alter the ability of IGF2R to dimerise,
but dimerisation may improve the avidity of the
receptor for ligands and increase the rate of internal-
isation (York et al. 1999, Byrd et al. 2000). Detailed
examination of our crystal structures conﬁrmed that
Gly1619R was remote from the hydrophobic dimeri-
sation surface in domain 12 that involved Pro1755 and
Tyr1741, and that there appeared no conformational
change in position of 1619 when comparing crystals
from domains 11–12 (where there is no dimerisation)
with those of 11–13 (where there is dimersiation) (not
shown, Brown et al. (2008)). These observations
suggested that Gly1619Arg would be unlikely to alter
the extent and stability of IGF2R dimerisation, particu-
larly as multiple domain interactions that regulate
dimerisation avidity between full length receptors.
Our data leads us to conclude that the Gly1619Arg
polymorphism is non-functional. It is possible that
there could be interactions with other non-synonymous
SNPs. For example, the location of the Gln1696Arg
(rs11552587) residue appeared closely localised to
Gly1619Arg in the crystal structure (Fig. 8), and may
directly interact to modify function. However, this SNP
is very rare in the populations examined so far (e.g.
0.009 allelic frequency in the Yoruba) and means that it
was unlikely that this interaction would be signiﬁcant.
However, it is possible that in certain populations the
rs629849 SNP is in LD with others that could contribute
to differential function or expression of the IGF2R
gene. Importantly, the SNPs with suggested LD with the
Figure 8 Structural localisation of Gln1696Arg and Gly1619Arg.
The rare SNP (rs11552587) results in a non-synonymous
polymorphism Gln1696Arg that modiﬁes an amino acid that also
locates close to Gly1619Arg in the region between domains11, 12
and 13. Other potential non-synonymous amino acids are also
shown (Gln/Q1832, Asp/D1514), but none are in linkage
disequilibrium with rs629849.
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and could possibly affect intron–exon splice sites.
Functional associations need not be correlated with
exon SNPs, as functional consequences may occur as a
result of intron SNPs, for example recently implicated
in altered methylation (Savage et al. 2007). Alterna-
tively, other non-synonymous SNPs in other regions of
the protein may result in unpredictable functional
changes. In order to completely understand the
complex function of the IGF2R protein and the effect
of genetic polymorphisms on its function, further
experimental evaluation of IGF2R polymorphisms
are warranted.
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